by Sandy Buck | Jul 25, 2013 | Biologics, OGD, Safety
Introduction Biopharmaceuticals have demonstrated unparalleled advances for the treatment of cancer, immune diseases, and other common medical conditions, and are the fastest growing segment of the pharmaceutical industry today. Worldwide sales of these agents are... by Christine Matusek | Apr 4, 2013 | Drugs, Financial Interest, OGD
Introduction TRICARE is the healthcare system employed by the Department of Defense (DoD) for use by the military. Healthcare, through TRICARE, is available to military service members (active duty, retired, and reserve) and dependents at almost no cost (dental... by Fazal Chaudhry | Feb 20, 2013 | Drugs, OGD
Introduction With the growing cost of pharmaceuticals, people are turning toward generic drugs. Many people are making the necessary cutbacks in their lives to meet the higher cost of living. One of the cutbacks is switching from brand-name medicines to generic... by Karan Sarna | Feb 7, 2013 | Drugs, OGD, Safety
Introduction For years, generic drugs have been taking over the pharmaceutical industry as the more cost-efficient option compared to brand names. Americans fill one billion prescriptions for generic medications yearly and rely on them to work just as well as brand... by Oksana L | Jan 26, 2013 | Drugs, FDA, OGD
Introduction For many years the FDA, doctors, and pharmacists believed and encouraged consumers that generic drugs were indistinguishable to brand drugs. This belief allowed payers to refuse to pay for brand drugs. In various ways purchasing generic drugs seemed to be... by Denise Daley | Jan 8, 2013 | OGD, REMS
Introduction Innovator (brand-name) drug companies spend millions of dollars to develop a single, new innovator drug. It is therefore understandable that they would want competing drugs to remain off the market as long as possible. Many innovator drug companies have...
Recent Comments